SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease : Expert Consensus Statements by KASID
Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, is threatening global health worldwide with unprecedented contagiousness and severity. The best strategy to overcome COVID-19 is a vaccine. Various vaccines are currently being developed, and mass vaccination is in progress. Despite the very encouraging clinical trial results of these vaccines, there is insufficient information on the safety and efficacy of vaccines for inflammatory bowel disease (IBD) patients facing various issues. After reviewing current evidence and international guidelines, the Korean Association for the Study of Intestinal Diseases (KASID) developed an expert consensus statement on COVID-19 vaccination issues for Korean IBD patients. This expert consensus statement emphasizes that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination be strongly recommended for IBD patients, and it is safe for IBD patients receiving immunomodulatory therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi - 78(2021), 2 vom: 25. Aug., Seite 117-128 |
| Sprache: |
Koreanisch |
|---|
| Beteiligte Personen: |
Lee, Yoo Jin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 18.10.2021 Date Revised 18.10.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.4166/kjg.2021.110 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329895370 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329895370 | ||
| 003 | DE-627 | ||
| 005 | 20231225210120.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||kor c | ||
| 024 | 7 | |a 10.4166/kjg.2021.110 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1099.xml |
| 035 | |a (DE-627)NLM329895370 | ||
| 035 | |a (NLM)34446634 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a kor | ||
| 100 | 1 | |a Lee, Yoo Jin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease |b Expert Consensus Statements by KASID |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.10.2021 | ||
| 500 | |a Date Revised 18.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, is threatening global health worldwide with unprecedented contagiousness and severity. The best strategy to overcome COVID-19 is a vaccine. Various vaccines are currently being developed, and mass vaccination is in progress. Despite the very encouraging clinical trial results of these vaccines, there is insufficient information on the safety and efficacy of vaccines for inflammatory bowel disease (IBD) patients facing various issues. After reviewing current evidence and international guidelines, the Korean Association for the Study of Intestinal Diseases (KASID) developed an expert consensus statement on COVID-19 vaccination issues for Korean IBD patients. This expert consensus statement emphasizes that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination be strongly recommended for IBD patients, and it is safe for IBD patients receiving immunomodulatory therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19 vaccines | |
| 650 | 4 | |a Inflammatory bowel diseases | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Kim, Seong-Eun |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Yong Eun |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Ji Young |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Hyun Joo |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Duk Hwan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Young Joo |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Byung Chang |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jae Gon |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Hee Chan |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Miyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Myung, Seung-Jae |e verfasserin |4 aut | |
| 700 | 0 | |a Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi |d 2003 |g 78(2021), 2 vom: 25. Aug., Seite 117-128 |w (DE-627)NLM14272808X |x 2233-6869 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2021 |g number:2 |g day:25 |g month:08 |g pages:117-128 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4166/kjg.2021.110 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2021 |e 2 |b 25 |c 08 |h 117-128 | ||